Search clinical trials for: BMS-986231 Formulation D

Total 433 results

Bristol-Myers Squibb

Completed

A Pharmacokinetics, Safety and Tolerability Study of Multiple Formulations of BMS-986231 in Healthy Participants

Heart Failure

United States
Bristol-Myers Squibb

Completed

Study With Healthy Japanese and Non-Asian Participants With BMS-986231

Heart Decompensation, Acute

United States
Bristol-Myers Squibb

Completed

Pharmacokinetics and Metabolism of [14C] BMS-986231 in Healthy Male Participants

Heart Decompensation, Acute

United States
Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986231 in Patients With Different Levels of Kidney Function

Renal Failure | Congestive Heart Failure | Kidney Failure | Cardiac Failure | Myocardial Failure

Poland, Czechia
Bristol-Myers Squibb

Completed

Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986331 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure (STANDUP AHF)

Heart Failure

France, Germany, Japan, Spain, United States, Argentina, Poland, Italy, Czechia, Greece, Netherlands, Canada, United Kingdom
Bristol-Myers Squibb

Completed

A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis

Pulmonary Fibrosis

Canada, France, United States, Argentina, Australia, Belgium, Brazil, Chile, China, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Spain, Taiwan, United Kingdom
Bristol-Myers Squibb

Completed

A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus

Lupus Erythematosus, Cutaneous

Germany
Bristol-Myers Squibb

Terminated

A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis

Rheumatoid Arthritis | Inflammatory Bowel Diseases | Psoriasis | Nonalcoholic Steatohepatitis | Ankylosing Spondylitis

Netherlands
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

Progressive Pulmonary Fibrosis

China, United States, Taiwan, Japan, Korea, Republic of, Hungary, Canada, Argentina, Australia, Austria, Belgium, Brazil, Chile, Colombia, Denmark, Finland, France, Germany, Greece, India, Ireland, Italy, Mexico, Peru, Poland, Portugal, Spain, Switzerla... and more
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

China, Taiwan, United States, Australia, Japan, Korea, Republic of, United Kingdom, Canada, Israel, Argentina, Austria, Belgium, Brazil, Chile, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, India, Ireland, Italy, ... and more
Bristol-Myers Squibb

Completed

An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function

Congestive Heart Failure | Liver Dysfunction | Heart Decompensation | Cardiac Failure | Liver Insufficiency | Myocardial Failure | Hepatic Failure

Hungary, Poland
Bristol-Myers Squibb

Terminated

BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome

Healthy Participants | Primary Sjögren's Syndrome

Germany, United States
Bristol-Myers Squibb

Completed

A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese Descent

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986235 in Healthy Subjects

Mediators of Inflammation

United States
Bristol-Myers Squibb

Recruiting

A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus

Lupus

United States, Argentina, Germany, Mexico, Poland, Romania, Bulgaria, Spain
Bristol-Myers Squibb

Completed

A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes

Diabetes Mellitus Type 2

United States, Canada
Bristol-Myers Squibb

Completed

A Study to Evaluate the Drug Levels, Metabolism, and Removal of BMS-986322 in Healthy Adult Male Participants

Healthy Male Participants

United States
Bristol-Myers Squibb

Completed

Relative Levels of BMS-986036 in Blood Plasma in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration Via Auto-injector Versus Pre-filled Syringe

Healthy Participants

United States
Bristol-Myers Squibb

Completed

An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function

NAFLD | Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis

Hungary, Czechia
Bristol-Myers Squibb

Withdrawn

Evaluate the Bioavailability Between 2 BMS-986141 Formulations in Healthy Participants

Healthy
Matthew Dallos
Bristol-Myers Squibb

Terminated

Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19

Solid Tumor | Sars-CoV2 | Hematological Malignancy

United States
Bristol-Myers Squibb

Completed

An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants

Cardiac Failure | Myocardial Failure

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Pharmacokinetics (Drug Levels and Metabolism), Safety, and Tolerability of BMS-986259 in Participants With Various Levels of Kidney Function

Renal Failure

United States
Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986036 Given to Healthy Participants

Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis | Liver Fibrosis | Hepatic Cirrhosis

United States
Bristol-Myers Squibb

Withdrawn

A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants

Hepatic Impairment

United States
Bristol-Myers Squibb
Cardioxyl Pharmaceuticals, Inc

Completed

A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers

Heart Failure
Bristol-Myers Squibb

Active, not recruiting

A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis

Psoriasis

United States, Australia, Canada, Japan, United Kingdom
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986325 in Healthy Japanese Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Terminated

A Phase 1, First-in-Human Study of BMS-986421 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Withdrawn

A Single and Multiple Ascending Dose Study of BMS-986318 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study to Test the Effects of BMS-986036 on the Body in Healthy Japanese and Non-Japanese Subjects

Metabolics

United States
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Participants With Atopic Dermatitis

Dermatitis, Atopic

France, Czechia, Germany, Poland, Spain
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327

Healthy Participants | Idiopathic Pulmonary Fibrosis (IPF)

United States
Bristol-Myers Squibb

Terminated

A Study of BMS-986224 in Healthy Subjects and Heart Failure Patients With Reduced Ejection Fraction

Heart Failure

Spain, United Kingdom, Netherlands, Czechia, Poland
Bristol-Myers Squibb

Completed

An Investigational Study to Evaluate the Effects of Experimental Medication BMS-986256 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study of BMS-986171 in Healthy People to Assess Safety, to Measure Blood Levels of Drug, and to Find Out What the Drug Does to the Body

Liver Fibrosis/NASH

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986278 in Healthy Chinese Participants

Healthy Volunteers

China
Bristol-Myers Squibb

Completed

Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure

Acute Decompensated Heart Failure

United Kingdom, Israel, Argentina, Czechia, Greece, Poland
Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C

Liver Fibrosis | Hepatic Cirrhosis

United States
Bristol-Myers Squibb

Completed

A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

Non-Alcoholic Steatohepatitis

United States
Bristol-Myers Squibb

Completed

A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

Non-Alcoholic Steatohepatitis

United States
Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986278 Given to Healthy Participants

Healthy Participants

United Kingdom, Netherlands
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

Melanoma

Spain, United States, Italy, Chile, Greece, Argentina
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Healthy Participants

Healthy Participants

Germany
Bristol-Myers Squibb

Recruiting

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

United States, Taiwan, Japan, Brazil, Colombia, Germany, Poland, Puerto Rico, China, Mexico, Argentina, France, Chile, Australia, India, Spain, United Kingdom, Romania, Ireland
Bristol-Myers Squibb

Active, not recruiting

A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors (RELATIVITY 059)

Advanced Solid Tumors

China
Bristol-Myers Squibb

Withdrawn

A Study to Evaluate the Drug Levels and Safety of Pegbelfermin in Healthy Overweight and Obese Chinese and Korean Participants

Healthy Participants

China, Korea, Republic of
Edward Kim
Bristol-Myers Squibb; National Cancer Institute (NCI)

Terminated

BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditions

United States
Bristol-Myers Squibb

Completed

An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment (ADVISE)

Advanced Cancer

United States

Search clinical trials for: BMS-986231 Formulation D

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations